India MCA Insolvency Liquidation Filings — February 05, 2026

Ongoing CIRP with board meeting scheduled Feb 11, 2026 for Q3FY26 unaudited results (no metrics disclosed), bearish sentiment and high risk

NCLT Hyderabad-directed newspaper publication on Feb 5, 2026 signaling insolvency entry, critical risk and bearish sentiment in pharma sector

NCLT-supervised meetings for equity shareholders, NCD holders, secured/unsecured creditors for amalgamation scheme, high risk despite neutral sentiment

Outcome of 3rd CoC meeting on Feb 5, 2026 in ongoing CIRP (no decisions or claims disclosed), bearish sentiment and high risk

Corporate insolvency proceedings flagged with high risk and 7/10 materiality, no resolution details

Newspaper notices for equity/NCD/secured creditor meetings under Reg 30, neutral but underscores restructuring needs

Q3FY26 and 9MFY26 results approved (no metrics) alongside Bindals acquisition under NCLT plan, neutral sentiment with strategic upside

Equity acquisition in Bindals Spong Industries via NCLT-approved resolution plan, neutral sentiment but indicates successful bidder status

Reached 'resolution plan approved' stage in insolvency, potential discounted valuation for acquirer

Dual filings on NCLT amalgamation (high risk vs low risk disclosures) highlight creditor involvement without scheme terms

CIRP progression to 3rd CoC without outcomes or plans disclosed, persistent high risk

Lack of default/claims details post-NCLT publication increases insolvency uncertainty

Ongoing insolvency proceedings with no financial/creditor details, board meeting Feb 11 may reveal distress depth

Critical risk from Hyderabad Bench publication, no disclosed claims or timelines heightens default uncertainty

High risk from NCLT creditor meetings involving secured/unsecured holders and NCDs, potential dilution without terms

3rd CoC meeting outcome undisclosed, liquidation risk if no viable plan approved

Multiple flags on CIRP involvement, high risk (Filing 5) with medium risk on acquisitions

Bindals equity buy under NCLT plan lacks deal value, share count, liabilities; integration/execution risks post-resolution

Routine notices mask underlying restructuring, low materiality but tied to high-risk scheme

No PoP financials, insider activity, or guidance in CIRP context amplifies bearish outlook

Pharma insolvency signal without metrics could trigger peer contagion

CIRP without plan details post-3rd CoC raises liquidation probability

Strategic buy of sponge steel assets via IBC resolution plan at likely discounted valuation, enables sector expansion

Successful NCLT resolution applicant for Bindals, potential low-cost entry into sponge iron amid steel M&A

Post-NCLT approval stage offers revival potential under Scan Steels ownership

NCLT amalgamation could streamline operations if creditor approvals secured, neutral sentiment

Feb 11 board meeting for Q3FY26 results may disclose CIRP progress or resolution hints

Post-3rd CoC developments could yield viable plan, monitor for bidder emergence

NCLT publication starts formal process, potential for strong resolution plan in pharma assets

Scan-Bindals deal exemplifies consolidation opportunities in distressed steel via NCLT resolutions

4/8 filings (KSS, Radhagobind, Scan Steels, Aster) in active CIRP/NCLT insolvency, indicating rising corporate distress without disclosed debt metrics

4/8 involve NCLT orders (newspaper pubs for Aster/Share India, CoC for Radhagobind, schemes), common restructuring gateway with high dilution risks

3/8 Scan Steels filings highlight resolution acquisitions (Bindals), potential undervalued assets vs execution risks

Share India dual filings (high/low risk) show neutral sentiment in amalgamation schemes, less acute than pure CIRP

8/8 lack PoP trends, financial ratios, insider activity, creditor claims; elevates uncertainty, favors short-term trading over holds

5/8 at 7-10/10 materiality (Aster 10/10, KSS/Radhagobind 9/10), prioritizing monitoring despite no quant data

Q3/9M FY26 unaudited results disclosure, potential CIRP financial insights, Feb 11, 2026

Post-publication creditor claims/resolution timelines, Hyderabad Bench updates imminent

NCLT-supervised equity/NCD/creditor meetings for amalgamation, dates/venue pending post-Feb 5 notice

Outcomes/decisions from 3rd CoC, watch for plan approvals or liquidation risks

Unaudited financials approved but undisclosed, monitor BSE for release and PoP trends

Execution on NCLT-approved acquisition, watch for deal terms, liabilities, synergies disclosure

Shareholder/creditor approvals in amalgamation, dilution risks if compromises needed

General watch for resolution plan approvals, bidder announcements, or liquidations post-Feb 5 cluster